In a randomized trial, three drug regimens for procedural sedation were equivalent, but the analysis was flawed.
For procedural sedation, the advantage of propofol is its short duration; its disadvantage is dose-related respiratory suppression. The advantage of ketamine is absence of respiratory suppression; its disadvantage is longer duration and emergence dysphoria, especially in adults. Investigators randomized 271 patients undergoing deep sedation to receive propofol, a 1:1 mixture of propofol and ketamine, or a 4:1 mixture of propofol and ketamine.
Emergence phenomena were more common in the group that received more ketamine (occurring in 21% of the 1:1 propofol/ketamine group vs. 8% of the propofol group and 10% of the 4:1 propofol/ketamine group). Respiratory suppression was more common in the groups that received more propofol (e.g., hypoxia in…
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals